Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Webinars
  4. Applications of Liquid Biopsy - Webinar Series

Applications of Liquid Biopsy Webinar Series - Lung Cancer

Aired live on 27 Oct 2021

ESMO-Webinar-Series-Applications-of-Liquid-Biopsy-Lung-Cancer-1000x250
Applications of Liquid Biopsy in Lung Cancer

Chair: Tony Mok
Speakers: Christian Rolfo, Maximilian Diehn

ESMO-Webinar-Series-Applications-of-Liquid-Biopsy-Lung-Cancer-1000x250

Login to get immediate access to this content.

Login

Learning objectives: 

  • Understand the current status of minimal residual disease and plasma monitoring for resectable lung cancer
  • Understand the role of plasma-based cfDNA testing in management of EGFR or ALK positive lung cancer
  • Understand novel technologies in liquid biopsy for lung cancer

This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and to discuss how tumour heterogeneity and evolution assessed via liquid biopsy assays may improve lung cancer treatment strategies.s.

Programme

  • Welcome and Introduction, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
  • Current Status of MRD and Plasma Monitoring for Resectable Lung Cancer, Prof. Christian Rolfo, Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, NY, US
  • The Role of plasma-based cfDNA Testing in Management of EGFR or ALK Positive Lung Cancer, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China
  • Novel Technology in Liquid Biopsy for Lung Cancer, Prof. Maximilian Diehn, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, US
  • Q&A
  • Closing Remarks, Prof. Tony Mok, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, SAR China

Related Links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.